Deucravacitinib for Psoriasis
(ARTISTYK Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
What data supports the effectiveness of the drug Deucravacitinib for treating psoriasis?
Deucravacitinib has been shown to be effective in treating moderate to severe plaque psoriasis, with up to 58.4% of patients experiencing symptom improvement in clinical trials. It was also more effective than placebo and another drug, apremilast, in reducing psoriasis severity in Japanese patients.12345
Is Deucravacitinib safe for humans?
Deucravacitinib has been tested in clinical trials and is generally considered safe, with common side effects including upper respiratory infections, increased blood enzyme levels, and mild skin issues like acne. In studies, the frequency of adverse events was similar to placebo, and no serious adverse events were reported.12467
How is the drug Deucravacitinib unique for treating psoriasis?
Deucravacitinib is unique because it is an oral medication that specifically targets TYK2, a protein involved in the immune response, using an allosteric mechanism (binding to a different site than the active site). This selectivity may offer a better safety profile compared to other treatments, and it has shown significant effectiveness in reducing psoriasis symptoms in clinical trials.12589
Research Team
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Eligibility Criteria
This trial is for men and women who have had stable plaque psoriasis for at least 6 months, with moderate-to-severe symptoms. Participants should have a noticeable impact on their quality of life due to psoriasis and be suitable candidates for phototherapy or systemic therapy, with at least 3% body surface area affected.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either deucravacitinib or placebo to evaluate the effect on quality of life
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Deucravacitinib
- Placebo
Deucravacitinib is already approved in United States, European Union, Canada for the following indications:
- Moderate to severe plaque psoriasis
- Moderate to severe plaque psoriasis
- Moderate to severe plaque psoriasis
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania